Apellis Pharmaceuticals Inc (NASDAQ:APLS) – Analysts at Cantor Fitzgerald issued their FY2020 earnings estimates for Apellis Pharmaceuticals in a research report issued on Thursday, August 1st. Cantor Fitzgerald analyst E. Piros expects that the company will post earnings per share of ($4.23) for the year. Cantor Fitzgerald currently has a “Overweight” rating and a $50.00 target price on the stock.
Apellis Pharmaceuticals (NASDAQ:APLS) last released its quarterly earnings data on Wednesday, May 8th. The company reported ($0.87) earnings per share for the quarter, missing the consensus estimate of ($0.67) by ($0.20).
NASDAQ APLS opened at $26.08 on Monday. Apellis Pharmaceuticals has a fifty-two week low of $11.45 and a fifty-two week high of $29.89. The company has a debt-to-equity ratio of 0.08, a current ratio of 8.67 and a quick ratio of 8.67. The stock has a 50 day simple moving average of $26.38.
Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Zurcher Kantonalbank Zurich Cantonalbank increased its position in Apellis Pharmaceuticals by 59.6% during the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,944 shares of the company’s stock valued at $75,000 after buying an additional 1,099 shares in the last quarter. SG Americas Securities LLC bought a new position in Apellis Pharmaceuticals during the 1st quarter valued at approximately $112,000. BNP Paribas Arbitrage SA increased its position in Apellis Pharmaceuticals by 250,533.3% during the 1st quarter. BNP Paribas Arbitrage SA now owns 7,519 shares of the company’s stock valued at $147,000 after buying an additional 7,516 shares in the last quarter. Metropolitan Life Insurance Co. NY increased its position in Apellis Pharmaceuticals by 356.7% during the 4th quarter. Metropolitan Life Insurance Co. NY now owns 12,216 shares of the company’s stock valued at $161,000 after buying an additional 9,541 shares in the last quarter. Finally, Bank of America Corp DE increased its position in Apellis Pharmaceuticals by 146.0% during the 4th quarter. Bank of America Corp DE now owns 17,533 shares of the company’s stock valued at $231,000 after buying an additional 10,407 shares in the last quarter. Institutional investors own 63.48% of the company’s stock.
Apellis Pharmaceuticals Company Profile
Apellis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the development of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. Its lead product candidate is APL-2 that is in Phase III clinical trials for the treatment of geographic atrophy in age-related macular degeneration and paroxysmal nocturnal hemoglobinuria diseases; and in Phase II clinical trials for the treatment of cold agglutinin and warm antibody autoimmune hemolytic anemia diseases, as well as in Phase II clinical trials to treat four types of glomerular diseases, such as C3 glomerulopathy, IgA nephropathy, primary membranous nephropathy, and lupus nephritis.
Recommended Story: Intrinsic Value
Receive News & Ratings for Apellis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Apellis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.